Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA have launched HALOETTE (etonogestrel and ethinyl estradiol) a vaginal hormonal contraceptive ring into the US market.
HALOETTE contraceptive is a generic version of NUVARING, a combined hormonal contraceptive flexible ring indicated for the prevention of pregnancy. According to IQVIA, NUVARING US brand and generic sales were approximately US$564 million for the 12 months ended November 2022.
Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra a milestone of EUR1.6 million.
We are pleased to announce the launch of HALOETTE in the US. This is another example of our commitment to providing women with more contraceptive choice. Mayne Pharma continues to expand its women’s health portfolio with the recent launch of NEXTSTELLIS (estetrol/drospirenone) in the US and Australia, and our new license agreement for ANNOVERA, IMVEXXY and BIJUVA from TherapeuticsMD,” CEO, Shawn O’Brien, said.
